Regenerex Pharma Financials

No, Regenerex Pharma (RGPX) reported a net income of -$2.5M in fiscal year 2025.

Regenerex Pharma (RGPX) had EBITDA of -$1.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Regenerex Pharma (RGPX) generated -$1.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Regenerex Pharma (RGPX) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Regenerex Pharma (RGPX) invested $662K in research and development during fiscal year 2025.

Regenerex Pharma (RGPX) had 281M shares outstanding as of fiscal year 2025.

Regenerex Pharma (RGPX) had a current ratio of 0.13 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Regenerex Pharma (RGPX) had a return on assets of -200.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Regenerex Pharma (RGPX) had $653K in cash against an annual operating cash burn of $1.6M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Regenerex Pharma (RGPX) has negative shareholder equity of -$4.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Regenerex Pharma (RGPX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Regenerex Pharma (RGPX) has an earnings quality ratio of 0.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Regenerex Pharma (RGPX) has an interest coverage ratio of -5.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.